The Integrated CLL scoring system (ICSS) divided patients into three groups based on cytogenetic abnormalities detected by FISH, IGHV mutation status, and CD38 expression to classify risk groups (low, medium, and high). The gene discussed is CD38; the disease is B-cell chronic lymphocytic leukemia.